Lyka Labs Limited share price
NSE: LYKALABS · ISIN INE933A01014
Key numbers
- Market cap
- ₹ 310 Cr
- Current price
- ₹ 85.85
- 52-week high / low
- ₹ 101 / 44
- Stock P/E
- -
- Book value
- ₹ 25.9
- Dividend yield
- 0.00%
- ROCE
- -6.1%
- ROE
- -10.2%
- Debt to equity
- 0.53
- Sales growth (3 yrs)
- 13.3%
- Profit growth (3 yrs)
- -
- 1-year return
- -14.5%
About Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations for human and animal healthcare in India and internationally. It offers injectable critical care solutions, anti-infectives, antifungals, anti-ulcer therapies, oncology support, cardiovascular therapies, and women's healthcare solutions such as gonadotropins, hormonal therapies, and haematinic formulations. The company also develops pharmaceutical and nutritional solutions for livestock, poultry, equine, and companion animals. In addition, it engages in sterile injectable manufacturing, advanced lyophilization technology, liposomal drug delivery, quality assurance and quality control systems, and stability testing and validation services. The company offers its products in various forms, including lyophilized, liquid, and dry powder injections, as well as ointments, creams, and lotions. It also exports its products. The company was incorporated in 1976 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 33 | 37 | 31 | 28 | 42 |
| Operating profit | 4 | -3 | 2 | -6 | 5 |
| Net profit | 1 | -3 | -0 | -8 | 2 |
| EPS (₹) | 0.25 | -0.94 | 0.00 | -2.13 | 0.57 |
Peers in Biotechnology
Data for information only, not investment advice. Prices end of day.